LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
about
Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment responseEpigenome-Wide Association Studies (EWAS) in CancerAssociation between Long Interspersed Nuclear Element-1 Methylation and Relative Telomere Length in Wilms TumorPrecision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cellsDemethylating Agents in the Treatment of CancerMethylation Levels of LINE-1 As a Useful Marker for Venous Invasion in Both FFPE and Frozen Tumor Tissues of Gastric CancerLINE-1 hypomethylation is not a common event in preneoplastic stages of gastric carcinogenesis.Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.Cross-contamination of a UROtsa stock with T24 cells--molecular comparison of different cell lines and stocksA higher degree of LINE-1 methylation in peripheral blood mononuclear cells, a one-carbon nutrient related epigenetic alteration, is associated with a lower risk of developing cervical intraepithelial neoplasia.Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patientsMethylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insultsMaternal DNA hypomethylation and congenital heart defectsNasal cell DNA methylation, inflammation, lung function and wheezing in children with asthma.Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications.A Whole Methylome CpG-SNP Association Study of Psychosis in Blood and Brain TissueBiological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia.Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.Hypomethylating agents for urologic cancers.Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.Clinical implications of the LINE-1 methylation levels in patients with gastrointestinal cancer.Targeting the cancer epigenome for therapy.Combined analysis of DNA methylation and cell cycle in cancer cells.Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.Analysis of pollutant-induced changes in mitochondrial DNA methylation.Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes.Quantitative comparison of DNA methylation assays for biomarker development and clinical applications.SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial.
P2860
Q27694612-C8531948-1CD6-4190-BD39-65A185F2F60EQ28310536-E916D99A-610C-4D31-B070-2E1322FD953DQ28389928-A1BA6986-A2E7-4D62-95CE-30F91A96A7C2Q33525767-86258F71-D004-494E-9CA0-61E41CF576B9Q33678040-5CB6BF4A-3A3F-43A8-8290-A0432F9423D1Q33775120-EAECD6CA-1D8C-4400-9E2F-7E3F7F040094Q33881018-62EF8BD2-6031-422C-A821-10A4DCEA77C4Q34101643-431ACF62-BAF6-40B0-91A2-EE4A4AB5AF2AQ34731286-567F77EF-A5BB-4576-9C2C-CA5C2B6DD612Q34762723-7711546E-55C3-4F6E-B532-BCE8887D8EFAQ35069309-5FC9D68E-F66E-4499-94EA-F8290F42E7FEQ35090701-C802DF96-986A-47A7-90BB-3502987BA8E5Q35200946-ACD023E6-5888-45C2-A7FE-1A102F4F939EQ35814618-180C2021-F5DF-40ED-B245-BD8C5D7F4706Q36001900-92CFE826-8975-4B6B-B1F0-02625345CCCCQ36994826-4A21D0A7-68F8-46BB-B417-D7515E807FC2Q37179155-92F328A5-8101-4E22-BE42-77FD862B4DF0Q37585487-CEFF13FD-7DC0-403C-BC9F-0DF18C9C6476Q37854737-4F862A2F-5960-40DA-91D9-023B7F790675Q37962016-F56DAAB9-1825-4D90-9086-1A4A6502CF94Q38154781-8022EE62-C97B-4D07-B58B-EE0AD2D26017Q38821103-DFA301E0-6800-4C86-BB11-7A0474C73E42Q38926364-05EFEBC9-56FE-49A5-8693-F91387FAC409Q41576877-E124925D-D378-49A6-842C-CDFFE99CF240Q43183735-4B428F8A-AE41-40E5-AD28-3230E6EA611EQ43577534-DCDC2EC1-6CD5-472E-B983-6AED2CC3ED9AQ45102064-A5E09ABE-6E32-4966-BF78-1C737CB35134Q50620646-3987E580-A59D-453B-BA4E-13A92D6C2139Q52609425-A0CF00E6-54A0-474B-973B-90824A7065ED
P2860
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
LINE-1 methylation in plasma D ...... in patients with solid tumors.
@ast
LINE-1 methylation in plasma D ...... in patients with solid tumors.
@en
type
label
LINE-1 methylation in plasma D ...... in patients with solid tumors.
@ast
LINE-1 methylation in plasma D ...... in patients with solid tumors.
@en
prefLabel
LINE-1 methylation in plasma D ...... in patients with solid tumors.
@ast
LINE-1 methylation in plasma D ...... in patients with solid tumors.
@en
P2093
P2860
P356
P1433
P1476
LINE-1 methylation in plasma D ...... in patients with solid tumors.
@en
P2093
Allen Yang
Ana Aparicio
Brittany North
Christine Yoo
Daniel Weisenberger
Erin Horne
Lindsey Barske
Nizar Tannir
Peter Jones
Susan Groshen
P2860
P304
P356
10.4161/EPI.4.3.8694
P577
2009-04-06T00:00:00Z